

## Liver graft outcomes from donors with Vaccine Induced Thrombosis and Thrombocytopenia (VITT)

Hann, Angus; Hartog, Hermien; Nutu, Anisa; Quist, Katherine; Sanabria-mateos, Rebecca; Greenhall, George H. B.; Ushiro-lumb, Ines; Nicolson, Phillip L. R.; Cain, Owen; Oo, Ye H.; Chauhan, Abhishek; Lester, Will; Pollok, Joerg-matthias; Prachalias, Andreas; Isaac, John R.; Thorburn, Douglas; Forsythe, John; Sharif, Khalid; Neil, Desley A. H.; Mirza, Darius F.

DOI:  
[10.1111/ajt.16869](https://doi.org/10.1111/ajt.16869)

License:  
Other (please specify with Rights Statement)

*Document Version*  
Peer reviewed version

*Citation for published version (Harvard):*  
Hann, A, Hartog, H, Nutu, A, Quist, K, Sanabria-mateos, R, Greenhall, GHB, Ushiro-lumb, I, Nicolson, PLR, Cain, O, Oo, YH, Chauhan, A, Lester, W, Pollok, J, Prachalias, A, Isaac, JR, Thorburn, D, Forsythe, J, Sharif, K, Neil, DAH, Mirza, DF & Perera, MTPR 2021, 'Liver graft outcomes from donors with Vaccine Induced Thrombosis and Thrombocytopenia (VITT): United Kingdom multi-centre experience', *American Journal of Transplantation*. <https://doi.org/10.1111/ajt.16869>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

This is the peer reviewed version of the following article: (see citation), which has been published in final form at <https://doi.org/10.1111/ajt.16869>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley's version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

**Article type:** Letter to editor

**Title:**

## **Liver Graft Outcomes from Donors with Vaccine Induced Thrombosis and Thrombocytopenia (VITT): United Kingdom Multi-Centre Experience**

**Authors:**

Angus Hann MD<sup>1,2</sup>, Hermien Hartog PhD<sup>1,3</sup>, Anisa Nutu MD<sup>1</sup>, Katherine Quist BN<sup>4</sup>, Rebecca Sanabria-Mateos MD<sup>5</sup>, George H.B. Greenhall MBChB<sup>6</sup>, Ines Ushiro-Lumb<sup>6</sup>, Phillip LR Nicolson PhD<sup>7</sup>, Owen Cain MD<sup>8</sup>, Ye H Oo FRCP<sup>1,2</sup>, Abhishek Chauhan PhD<sup>1</sup>, Will Lester PhD<sup>7</sup>, Joerg-Matthias Pollok FRCS<sup>4,9</sup>, Andreas Prachalias FRCS<sup>5</sup>, John R Isaac FRCS<sup>1</sup>, Douglas Thorburn FRCP<sup>4,6</sup>, John Forsythe FRCS<sup>6</sup>, Khalid Sharif FRCS<sup>3</sup>, Desley AH Neil FRCPATH<sup>2,7</sup>, Darius F Mirza FRCS<sup>1,2,3</sup>, M. Thamara P.R. Perera FRCS<sup>1,3</sup>

**Affiliations:**

1. Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom
2. Institute of Immunology, University of Birmingham, United Kingdom
3. Birmingham Childrens Hospital, Birmingham, United Kingdom
4. Liver Unit, Royal Free Hospital, London
5. Liver Unit, Kings College Hospital, London
6. National Health Service Blood and Transplant Service, Bristol, United Kingdom
7. Department of Haematology, Queen Elizabeth Hospital Birmingham, United Kingdom
8. Department of Pathology, Queen Elizabeth Hospital Birmingham, United Kingdom
9. Department of surgery & Interventional Science, University College London, United Kingdom

**Word count:** 2779

**Corresponding author**

Mr. Thamara Perera FRCS

Consultant Liver Transplant Surgeon

Queen Elizabeth Hospital, Mindelsohn Way

Birmingham, United Kingdom B15 2GW

Telephone: 0044 12137 14064

Fax: 0044 121141 1804

E-mail: [Thamara.Perera@uhb.nhs.uk](mailto:Thamara.Perera@uhb.nhs.uk)

**ABBREVIATIONS:**

HAT: Hepatic artery thrombosis

HIT: Heparin induced thrombocytopenia

LT: Liver transplantation

PF4: Platelet factor 4

TMAT: Transplantation mediated alloimmune thrombocytopenia

UK: United Kingdom

VITT: Vaccine induced immune thrombocytopenia and thrombosis

**Dear Editor,**

Vaccine-induced immune thrombosis and thrombocytopenia (VITT) syndrome is a new entity, characterised by severe thrombocytopenia and multiple sites of thrombosis<sup>1</sup>. The presumed mechanism is driven by anti-platelet factor 4 (PF4) antibodies causing platelet activation<sup>1</sup>. Donors with VITT syndrome have a particular relevance for liver transplantation (LT), due to the associated risk of passenger lymphocyte syndrome, and a predisposition for porto-mesenteric or hepatic vein thrombosis all<sup>2</sup>. The early United Kingdom (UK) experience on pan-solid organ transplants from VITT donors has been briefly documented and sent a cautionary message to the transplant community<sup>3</sup>, meanwhile the recent French series only included one liver transplant recipient<sup>4</sup>. Our aim is to describe longitudinal outcomes of liver grafts transplanted in the UK from donors with VITT syndrome thus far, so that both clinicians and patient can more accurately consider the risk-benefit equation under the caveat emptor principle (“buyer beware”) when utilising these organs, as suggested by Wolfe et al<sup>5</sup>.

Prior to the initial description of VITT syndrome in early April 2021, seven LT were from donors with VITT syndrome, plus two further LT performed following the review of early outcomes, and appropriate risk-benefit assessments. All donors (n=8, aged between 22-55years) had catastrophic intracerebral haemorrhage or thrombosis, and had received the first dose of ChAdOx1 nCoV-19 vaccine 9 to 19 days before hospital admission. One liver was split into an extended right lobe and left lateral segment. Recipients’ (n=9, aged 2-43years) indications for LT included hepatoblastoma(1), seronegative hepatitis(1), late hepatic artery thrombosis(HAT, 2), primary sclerosing cholangitis (PSC,2), recurrent PSC(1), Budd-Chiari syndrome(1) and alcohol-related liver disease(1). Therapeutic anti-coagulation post-transplantation was empirically started in three recipients with Budd Chiari syndrome and late HAT. PF4 IgG-antibodies were assessed by enzyme linked immunosorbent assay and four recipients had positive (>0.40 optical density) levels early in the postoperative period (day 2-

18). None of these recipients had bleeding or thrombotic complications; two were commenced on therapeutic anticoagulation [Apixaban or fondaparinux]. One recipient was anticoagulated with argatroban and then danaparoid based on the donor diagnosis of VITT, and experienced intra-abdominal and gastrointestinal bleeding early post-transplant. Severe thrombotic events occurred in the two recipients of the split liver grafts derived from the same donor, requiring emergency re-transplantation within the first 7 postoperative days, but no anti-PF4 antibodies were detected. Histologic finding suggested vascular thrombosis was likely pre-existing in the donor (Figure 1). So far, all recipients in the UK have more than 3 months follow-up, and are alive at the time of writing with good liver functions, including two recipients that underwent re-transplantation.

Since this entity emerged, 19 brain-dead donors with VITT syndrome in the UK have had organs offered for transplantation, only the 9 liver grafts (from 8 donors) presented in this manuscript were transplanted. This signifies scepticism within the transplant community. Our current understanding, based on limited experience, is that safe transplantation of livers from these donors is still possible, with the main concern being pre-existing vascular thrombosis in the graft<sup>2</sup>. With the continued global administration of the ChAdOx1 nCoV-19 vaccine, donors with VITT syndrome are likely to continue and should be given the appropriate consideration for transplantation.

**ACKNOWLEDGEMENTS:**

Mr. Chris Callaghan, associate medical director NHSBT, United Kingdom for the support and contribution in data collection. Manuscript figures created with biorender.com.

## CONFLICTS OF INTEREST

### Authors:

Angus Hann has no conflicts of interest to disclose as per *the American Journal of Transplant*

Hermien Hartog has no conflicts of interest to disclose as per *the American Journal of Transplant*

Anisa Nutu has no conflicts of interest to disclose as per *the American Journal of Transplant*

Katherine Quist has no conflicts of interest to disclose as per *the American Journal of Transplant*

Rebecca Sanabria-Mateos has no conflicts of interest to disclose as per *the American Journal of Transplant*

George H.B. Greenhall has no conflicts of interest to disclose as per *the American Journal of Transplant*

Ines Ushiro-Lumb has no conflicts of interest to disclose as per *the American Journal of Transplant*

Phillip LR Nicolson has no conflicts of interest to disclose as per *the American Journal of Transplant*

Owen Cain has no conflicts of interest to disclose as per *the American Journal of Transplant*

Ye H Oo has no conflicts of interest to disclose as per *the American Journal of Transplant*

Abhishek Chauhan has no conflicts of interest to disclose as per *the American Journal of Transplant*

Will Lester has no conflicts of interest to disclose as per *the American Journal of Transplant*

Joerg-Matthias Pollok has no conflicts of interest to disclose as per *the American Journal of Transplant*

Andreas Prachalias has no conflicts of interest to disclose as per *the American Journal of Transplant*

John Isaac has no conflicts of interest to disclose as per *the American Journal of Transplant*

Douglas Thorburn has no conflicts of interest to disclose as per *the American Journal of Transplant*

John Forsythe has no conflicts of interest to disclose as per *the American Journal of Transplant*

Khalid Sharif has no conflicts of interest to disclose as per *the American Journal of Transplant*

Dessley AH Neil has no conflicts of interest to disclose as per *the American Journal of Transplant*

Darius F Mirza has no conflicts of interest to disclose as per *the American Journal of Transplant*


M. Thamara P.R. Perera has no conflicts of interest to disclose as per *the American Journal of Transplant*



## REFERENCES

1. Scully M, Singh D, Lown R, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med*. Apr 16 2021;doi:10.1056/NEJMoa2105385
2. Centonze L, Lauterio A, De Carlis R, Ferla F, De Carlis L. Successful Liver Transplantation From a Donation After Brain Death Donor With Cerebral Venous Sinus and Hepatic Veins Thrombosis Occurred After ChAdOx1 nCov-19 Vaccination. *Transplantation*. Jun 23 2021;doi:10.1097/tp.0000000000003875
3. Greenhall GHB, Ushiro-Lumb I, Pavord S, et al. Organ transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. Jul 2 2021;doi:10.1111/ajt.16735
4. Loupy A, Goutaudier V, Jacquelinet C, Kerbaul F. Solid organ procurement and transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia. *Am J Transplant*. Jul 7 2021;doi:10.1111/ajt.16751
5. Wolfe C, Humar A. Buyer beware: The risks of donor-derived vaccine-induced thrombosis and thrombocytopenia. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. Aug 17 2021;doi:10.1111/ajt.16802

**FIGURE 1**



**LEGEND:** Images demonstrating failed grafts; Left lateral segment (A&B), Extended right lobe (C-F). A) Slice of explanted left lateral segment with clot evident in portal vein (lower right). Inset demonstrates thrombus within peripheral hepatic vein branches. B) Histology image (Haematoxylin and Eosin stain) of explanted left lateral segment showing thrombus in portal vein and hepatic artery (arrow). C) White thrombus evident macroscopically in the hepatic vein (White arrow) and fresh thrombus in intrahepatic portal vein (Blue arrow). D) Haematoxylin and eosin stain of explanted liver showed organising thrombus with granulation tissue, suggesting it may have occurred within the donor. E & F - Haematoxylin and Eosin stain (E) and haematoxylin and Van Gieson (F) stain demonstrating thrombosed hepatic vein with early collagen (pale pink, white arrow) deposition around the thrombus. This suggests thrombosis had been organised and may have occurred prior to

transplant, rather than in the 4 post-operative days. The mature collagen within the vessel wall (dark pink) is marked with a blue arrow.

